Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Otitis Media Studies Can Use Four Trial Designs Under FDA Draft Guidance

Executive Summary

FDA's draft guidance for developing drugs to treat acute bacterial otitis media offers sponsors four possible superiority study designs

You may also be interested in...



FDA Loosens Otitis Media Antibiotic Requirements In Final Guidance

While it drops an invasive enrollment assay requirement, the revised guidance for drugs that fight childhood ear infections provides a clear path to getting pathogens targeted by an investigational anti-infective into labeling.

FDA Still Needs Convincing On Use Of Non-Inferiority Trials For CAP – Temple

Industry has provided little data supporting the use of non-inferiority trials as the basis for approval for community-acquired pneumonia, FDA Office of Medical Policy Director Bob Temple said at a recent workshop on clinical trial design for CAP

Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?

Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.
UsernamePublicRestriction

Register

PS049268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel